Source comparison
Quickcomparison
Dose Range PT-141 (Bremelanotide) 1.75–2 mg Kisspeptin-10 50–100 mcg Frequency As needed Once daily Administration Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Rapid (hours to days) Evidence Level Strong human trials (Phase 3 or
This comparison does not assign a generated winner or score.
- Dose Range
- PT-141 (Bremelanotide)
- 1.75–2 mg
- Kisspeptin-10
- 50–100 mcg
- Frequency
- As needed
- Once daily
- Administration
- Subcutaneous injection
- Cycle Length
- Ongoing/indefinite
- 4-6 weeks
- Onset Speed
- Rapid (hours to days)
- Evidence Level
- Strong human trials (Phase 3 or FDA approved)
- Moderate human trials (Phase 1-2)
- Efficacy